DVAX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DVAX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Dynavax Technologies's book value per share for the quarter that ended in Dec. 2024 was $4.76.
During the past 12 months, Dynavax Technologies's average Book Value Per Share Growth Rate was -1.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 38.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 115.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Dynavax Technologies was 258.30% per year. The lowest was -65.00% per year. And the median was -8.20% per year.
Dynavax Technologies's current price is $13.825. Its book value per share for the quarter that ended in Dec. 2024 was $4.76. Hence, today's PB Ratio of Dynavax Technologies is 2.91.
During the past 13 years, the highest P/B Ratio of Dynavax Technologies was 67.41. The lowest was 1.41. And the median was 5.42.
The historical data trend for Dynavax Technologies's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavax Technologies Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial |
![]() |
![]() |
0.53 | 1.81 | 4.55 | 4.80 | 4.76 |
Dynavax Technologies Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Book Value per Share | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
4.80 | 4.73 | 4.91 | 5.19 | 4.76 |
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's PB Ratio falls into.
Dynavax Technologies's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (596.8 | - | 0.0) | / | 125.5 | |
= | 4.76 |
Dynavax Technologies's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (596.8 | - | 0.0) | / | 125.5 | |
= | 4.76 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Dynavax Technologies (NAS:DVAX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Dynavax Technologies's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
David F Novack | officer: Senior Vice President | 39 YORKSHIRE DR, OAKLAND CA 94618 |
Francis Cano | director | 11 ACORN LANE, LOS ALTOS CA 94022 |
Justin Burgess | officer: Principal Accounting Officer | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608 |
Robert Janssen | officer: Chief Medical Officer and VP | C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Ryan Spencer | officer: Co-President and Senior VP | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753 |
Elaine D Sun | director | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Scott Dunseth Myers | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Kelly Macdonald | officer: SVP and CFO | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Peter R. Paradiso | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608 |
Julia Marie Eastland | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Brent Macgregor | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608 |
Peggy V Phillips | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
Robert Coffman | officer: Chief Science Officer and VP | C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710 |
Michael S Ostrach | officer: VP, CBO, and General Counsel | 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063 |
From GuruFocus
By Business Wire • 03-10-2025
By PRNewswire • 11-07-2024
By GuruFocus News • 03-06-2025
By GuruFocus News • 01-27-2025
By PRNewswire • 01-27-2025
By GuruFocus News • 02-21-2025
By GuruFocus News • 02-22-2025
By GuruFocus News • 11-08-2024
By PRNewswire • 01-13-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.